MPLT

Maplight Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000

$7.58Close $333.7MMarket cap $7.58 – $39.8052-week range Dec 3, 2026Next report

Highlights

Strengths

Volume drying up last 10 days 34% under the 50-day average

Cautions

Not in an uptrend 1 of 8 trend conditions
Lagging the market RS 2 · weaker than 98% of stocks over 12 months
Far from its high 81% below its 52-week high

Price

Filing Results Screen pick 52-week high and low Adjusted prices

Key figures

FY to Dec 31, 2025 · filed Aug 13, 2026

Off 12-month high 81%

1wk 4.9% price change

1mo 25.6% price change

12-month return 59% market up 11% · its own down 65%

F-score — — Not assessed

Altman Z — Unknown

P/E — price / earnings

PEG — P/E / EPS growth

P/B 0.7× price / book

Earnings yield 58.9% EBIT / enterprise value

Cheaper than — of the market · not assessed

Revenue growth — year on year

EPS growth — latest quarter

Sales growth — latest quarter

ROE 35% return on equity

Free cash margin — -$138.6M FCF

D/E — long-term debt / equity

Net debt / EBITDA —

Interest cover —EBIT / interest

Trade setup

ATR% 8.3% $0.63 a day · 2×ATR $6.32

RS 2 / 99 vs the universe

Trend 1 / 8 trend template

Relative volume 0.8× vs 50-day average

Up/down volume 0.68 50 sessions

Implied move — no option chain · report Dec 3, 2026

Contractions 3 77% → 48% → 13%

Pivot $8.58 11.7% below

Volume dry-up 0.7× 10 vs 50 sessions

Trend template · 1 of 8

150-day average above the 200-day: passes

Screen verdict

Did not qualify for any screen.

Warning signs

1 flagged

Shareholders diluted The share count rose 5682.9% over the year, from 1m to 44m shares. Each existing share owns a smaller fraction of the company than it did a year ago.

Last reported Aug 13, 2026

Last shock Jul 27, 2026-73% in one session11.1× volumeon an SEC filing-23% since

Financials

2 fiscal years · from filings

Net income Profit left after every cost, interest and tax for the year. A column below the line is a loss. Methodology -$161.2M

Free cash flow Cash from running the business less what it spent on equipment and buildings: the cash a year actually left behind, which profit alone does not show. Not shown for banks and insurers, whose cash moves with their loans. Methodology -$138.6M

Cash and long-term debt Cash on the balance sheet at the year's end beside debt due after a year. Net cash is cash less that debt; net debt is the shortfall. Debt some filers do not tag shows as a gap, not as zero. Methodology

Cash
Long-term debt

Shares outstanding Shares in issue at the year's end. A rising count means each share owns a smaller slice of the company (stock pay, share sales); a falling one, buybacks. The chart's scale is fitted to the count, so a small change looks large: read the percentage. Methodology 44.02m +5682.9% since FY2024

	FY2024Dec 31, 2024	FY2025Dec 31, 2025
Operating income	-$82.9M	-$169.1M
Net income	-$77.6M	-$161.2M
Earnings per share	-$105.38	-$18.56
Free cash flow	-$79.6M	-$138.6M
Cash	$38.3M	$46.7M
Shareholders' equity	-$193.6M	$458.4M
Shares outstanding	761.28k	44.02m

Filings

SEC EDGAR

Filed	Report	Period to	Lag
Aug 13, 2026	Quarterly ↗	Jun 30, 2026	44d
May 14, 2026	Quarterly ↗	Mar 31, 2026	44d
Mar 26, 2026	Annual ↗	Dec 31, 2025	85d
Dec 4, 2025	Quarterly ↗	Sep 30, 2025	65d

Current reports

Filed	Disclosed
Aug 13, 2026	Material agreement · Results · Unregistered share sale · Regulation FD ↗
Jul 27, 2026	Regulation FD · Other events ↗
Jun 24, 2026	Shareholder vote ↗
Jun 22, 2026	Regulation FD · Other events ↗
Jun 18, 2026	Director or officer change ↗
May 14, 2026	Results · Regulation FD ↗
Apr 29, 2026	Director or officer change ↗
Mar 26, 2026	Results · Regulation FD ↗
Jan 9, 2026	Results · Regulation FD ↗
Dec 4, 2025	Results · Regulation FD ↗
Oct 29, 2025	Unregistered share sale · Charter or bylaws · Other events ↗